X
[{"orgOrder":0,"company":"RS Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"RS Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RS Oncology Reports Positive Phase 1 Data for RSO-021 in Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by RS Oncology
Filters
Companies By Therapeutic Area
Details:
RSO-021 (thiostrepton) is a novel small molecule, that irreversibly binds to PRX3. It is being evaluated for the treatment of malignant pleural mesothelioma.
Lead Product(s):
Thiostrepton
Therapeutic Area: Oncology
Product Name: RSO-021
Highest Development Status: Phase I/ Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 03, 2024
Details:
RSO-021 (thiostrepton) is a novel small molecule, that irreversibly binds to mitochondrial peroxiredoxin 3 (PRX3). It is being evaluated in phase 2 clinical trials for the treatment of malignant pleural mesothelioma and metastatic disease to the lung.
Lead Product(s):
Thiostrepton
Therapeutic Area: Oncology
Product Name: RSO-021
Highest Development Status: Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 01, 2024